Marshall Urist Sells 13,684 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total transaction of $721,831.00. Following the completion of the transaction, the executive vice president owned 18,197 shares of the company’s stock, valued at $959,891.75. The trade was a 42.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $54.50 on Friday. The firm has a 50 day moving average of $49.03 and a 200-day moving average of $43.91. The stock has a market capitalization of $31.38 billion, a PE ratio of 37.08, a PEG ratio of 1.47 and a beta of 0.40. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 12 month low of $32.15 and a 12 month high of $54.64.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. On average, equities research analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio is currently 63.95%.

Hedge Funds Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. LM Advisors LLC acquired a new position in Royalty Pharma in the 4th quarter valued at approximately $26,000. Lloyd Advisory Services LLC. acquired a new position in Royalty Pharma in the 4th quarter valued at approximately $30,000. Smartleaf Asset Management LLC increased its position in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. Private Trust Co. NA increased its position in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 288 shares during the period. Finally, Blue Trust Inc. increased its position in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 437 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. upped their price objective on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Finally, Citigroup upped their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.